scholarly journals Viruses and Mycoplasma pneumoniae are the main etiological agents of community‐acquired pneumonia in hospitalized pediatric patients in Spain.

2021 ◽  
Author(s):  
Enrique Otheo ◽  
Mario Rodríguez ◽  
Cinta Moraleda ◽  
Sara Domínguez‐Rodríguez ◽  
María Dolores Martín ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Pediatric Patients ◽  
Community Acquired Pneumonia ◽  
Etiological Agents

scholarly journals Sequential Mycoplasma pneumoniae pneumonia and Chromobacterium violaceum skin abscess in a pediatric patient

2017 ◽  
Vol 11 (08) ◽  
pp. 656-661 ◽  
Author(s):  
Weizhen Guo ◽  
Iris Wai Sum Li ◽  
Xi Li ◽  
Hua Xu ◽  
Dongrong Lu ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Pediatric Patients ◽  
Community Acquired Pneumonia ◽  
Chromobacterium Violaceum ◽  
Respiratory Pathogen ◽  
First Case ◽  
History Of ◽  
The Right ◽  
Super Infection ◽  
Mycoplasma Pneumoniae Pneumonia

Mycoplasma pneumoniae is a common atypical respiratory pathogen causing community-acquired pneumonia in children. Co-infection with other respiratory viruses is common in pediatric patients but super-infection with bacteria other than Streptococcus pneumoniae and Haemophilus influenzae is rare. The first case of Chromobacterium violaceum infection incubated during and manifested after pneumonia caused by Mycoplasma pneumoniae in a 12-month old girl without any known history of immunodeficiency is here reported. The patient developed fever with redness and swelling over the middle phalanx of the right hand index finger which progressed to the formation of skin abscess. Following a course of intravenous meropenem and surgical drainage of the skin abscess, the patient fully recovered and was discharged.

scholarly journals Prediction Model for Severe Mycoplasma Pneumoniae Pneumonia in Pediatric Patients by Admission Laboratory Indicators

2021 ◽  
Author(s):  
Qing Chang ◽  
Hong-Lin Chen ◽  
Neng-Shun Wu ◽  
Yan-Min Gao ◽  
Rong Yu ◽  
...  
Keyword(s):  
Prediction Model ◽  
Mycoplasma Pneumoniae ◽  
Eosinophil Count ◽  
Goodness Of Fit ◽  
Pediatric Patients ◽  
Community Acquired Pneumonia ◽  
Goodness Of Fit Test ◽  
Independent Risk Factors ◽  
Mycoplasma Pneumoniae Pneumonia ◽  
Actual Incidence

Abstract Objective The purpose of this study was to develop a model for predicting severe mycoplasma pneumoniae pneumonia (SMMP) in pediatric patients with MMP on admission by laboratory indicators. Methods Pediatric patients with MPP from January 2019 to December 2020 in our hospital were enrolled in this study. SMMP was diagnosed according to guideline for diagnosis and treatment of community acquired pneumonia in children (2019 version). Prediction model was developed according to the admission laboratory indicators. ROC curve and Goodness of fit test were analyzed for the predictive value. Results A total of 233 MMP patients were included in the study, with 121 males and 112 females, aged 4.541 (1–14) years. Among them, 84 (36.1%, 95% CI 29.9%-42.6%) pediatric patients were diagnosed as SMPP. Some admission laboratory indicators (IgM, eosinophil proportion, eosinophil count, hemoglobin, ESR, total protein, albumin and prealbumin) were found statistically different (P < 0.05) between non-SMMP group and SMMP group. Logistic regress analysis showed IgM, eosinophil proportion, eosinophil count, ESR, and prealbumin were independent risk factors for SMMP. According to these five admission laboratory indicators, Nomograph prediction model was developed. The AUC of the Nomograph prediction model was 0.777, and the goodness of fit test showed that the predicted incidence of the model was consistent with the actual incidence (χ2 = 244.51, P = 0.203). Conclusion We developed a model for predicting SMMP in pediatric patients by admission laboratory indicators. This model has good discrimination and calibration, which provides a basis for the early identification SMMP on admission.

scholarly journals Differences in the Frequency of 23S rRNA Gene Mutations in Mycoplasma pneumoniae between Children and Adults with Community-Acquired Pneumonia: Clinical Impact of Mutations Conferring Macrolide Resistance

2012 ◽  
Vol 56 (12) ◽  
pp. 6393-6396 ◽  
Author(s):  
Soo Jin Yoo ◽  
Hyo-Bin Kim ◽  
Sang-Ho Choi ◽  
Sang-Oh Lee ◽  
Sung-Han Kim ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Pediatric Patients ◽  
Gene Mutations ◽  
Community Acquired Pneumonia ◽  
Clinical Impact ◽  
Macrolide Resistance ◽  
23S Rrna ◽  
Rrna Gene ◽  
Content Type ◽  
23S Rrna Gene

ABSTRACTWe investigated the frequency and clinical significance of macrolide resistance in adult and pediatric patients with community-acquired pneumonia from aMycoplasma pneumoniaeinfection. The frequency of the A2063G mutation in the 23S rRNA gene was significantly higher in children than in adults (61.3% [19/31] and 13.3% [8/60], respectively;P< 0.001). Patients with macrolide-resistantM. pneumoniaeinfections showed a longer duration of fever (P= 0.021) and required a longer duration of antibiotic treatment (P= 0.007).

scholarly journals Increased Macrolide Resistance of Mycoplasma pneumoniae in Pediatric Patients with Community-Acquired Pneumonia

2007 ◽  
Vol 52 (1) ◽  
pp. 348-350 ◽  
Author(s):  
Miyuki Morozumi ◽  
Satoshi Iwata ◽  
Keiko Hasegawa ◽  
Naoko Chiba ◽  
Reiko Takayanagi ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Pediatric Patients ◽  
Community Acquired Pneumonia ◽  
Macrolide Resistance ◽  
23S Rrna ◽  
Resistant Strains ◽  
Domain V

ABSTRACT Among 380 Mycoplasma pneumoniae isolates from 3,678 pediatric patients with community-acquired pneumonia, 50 macrolide-resistant strains had an A2063G transition in domain V of the 23S rRNA, whereas 5 had an A2064G transition. These resistant strains increased rapidly from April 2002 to December 2006.

scholarly journals Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia

2005 ◽  
Vol 49 (10) ◽  
pp. 4128-4136 ◽  
Author(s):  
Monica Fonseca-Aten ◽  
Christine M. Salvatore ◽  
Asunción Mejías ◽  
Ana M. Ríos ◽  
Susana Chávez-Bueno ◽  
...  
Keyword(s):  
Bronchoalveolar Lavage ◽  
Mycoplasma Pneumoniae ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Placebo Treatment ◽  
Community Acquired Pneumonia ◽  
Peptide Deformylase ◽  
Necrosis Factor Alpha ◽  
Days Of Therapy ◽  
Ifn Γ

ABSTRACT Mycoplasma pneumoniae is a major cause of community-acquired pneumonia. We evaluated the efficacy of LBM415, a novel peptide deformylase inhibitor antimicrobial agent, for the treatment of M. pneumoniae pneumonia in a mouse model. Eight-week-old BALB/c mice were intranasally inoculated once with 107 CFU of M. pneumoniae. Groups of mice were treated with LBM415 (50 mg/kg of body weight) or placebo subcutaneously daily for 13 days, starting 24 h after inoculation. Groups of mice were evaluated at the baseline; at days of treatment 1, 3, 6, and 13; and at 7 days after treatment. The MIC of LBM415 against M. pneumoniae was <0.005 μg/ml. LBM415-treated mice had significantly lower bronchoalveolar lavage fluid M. pneumoniae concentrations than placebo-treated mice on days 6 and 13 of treatment. Compared with placebo treatment, therapy with LBM415 significantly decreased lung histopathology scores at days 3, 6, and 13 of treatment and at 7 days after treatment. Airway obstruction was significantly lower in LBM415-treated mice than in placebo-treated mice on days 1, 3, and 6 of treatment and after 7 days of therapy, while airway hyperresponsiveness was significantly lower only on day 3 of therapy. The bronchoalveolar lavage fluid concentrations of tumor necrosis factor alpha, gamma interferon (IFN-γ), interleukin-6 (IL-6), IL-12, KC (functional IL-8), monocyte chemotactic protein 1, macrophage inflammatory protein 1α, monokine induced by IFN-γ, and IFN-inducible protein 10 were significantly reduced in LBM415-treated mice compared with the levels in placebo-treated mice. There were no differences in the bronchoalveolar lavage fluid concentrations of granulocyte-macrophage colony-stimulating factor, IL-1β, IL-2, IL-4, IL-5, and IL-10 between the two groups of mice. LBM415 therapy had beneficial microbiologic, histologic, respiratory, and immunologic effects on acute murine M. pneumoniae pneumonia.

scholarly journals Clinical Presentation and Bacterial Etiology of Adult Community Acquired Pneumonia

2017 ◽  
Vol 34 (3) ◽  
pp. 128-134
Author(s):  
Md Abdus Salam ◽  
Md Robed Amin ◽  
Quazi Tarikul Islam
Keyword(s):  
Streptococcus Pneumoniae ◽  
Blood Culture ◽  
Mycoplasma Pneumoniae ◽  
Chlamydia Pneumoniae ◽  
Community Acquired Pneumonia ◽  
Sputum Culture ◽  
Gram Positive ◽  
Gram Negative ◽  
The Mean ◽  
Gram Positive Cocci

Introduction: Pneumonia is a worldwide, serious threat to health and an enormous socio-economic burden for health care system. According to recent WHO data, each year 3-4 million patients die from pneumonia. The clinical presentations and bacterial agents responsible for community acquired pneumonia (CAP) varies according to geography and culture.Methods: A cross sectional observational study conducted among the 53 consecutive patients with a clinical diagnosis of CAP in admitted patient in the department of Medicine, DMCH, during January 2010 to December 2010. Hematological measurements (TC of WBC, Hb%, ESR, platelet count), blood culture, chest X-ray P/A view, sputum for Gram staining and culture sensitivity, sputum for AFB, blood urea and random blood sugar were done in all cases. ELISA for IgM antibody of Mycoplasma pneumoniae and Chlamydia pneumoniae were done in sputum culture negative cases.Results: The mean (±SD) age was 38.9±17.3 years and Male female ratio was 3:1. Fever, chest pain and productive cough were the most common clinical features. The mean (±SD) respiratory rate was 23.0±2.8 /minute . COPD and DM were found in 17.0% and 5.7% of patients respectively . Blood culture was found positive in only 1.9% of the study patients. Gram positive Cocci 62.26%, Gram negative Bacilli 9.43%, mixed Gram positive cocci and Gram negative bacilli 11.32% and Gram negative Cocco Bacilli 1.9% were observed and in 15.03 % cases, no bacteria could be seen. Sputum culture revealed 53.8% streptococcus pneumoniae, 26.9% Klebsiella pneumonia as predominant organism. Mycoplasma pneumoniae and Chlamydia pneumoniae were found in 7.4% and 3.7% respectively by serological test. For Streptococcus pneumoniae, sensitive antibiotics were Amoxyclav and Levofloxacin. For Gram negative bacilli and coccobacilli, more sensitive antibiotics were Meropenem, Ceftriaxone, and Clarithromycin. The best sensitive drug were found meropenem. The mean (±SD) duration of hospital stay was 5.0±1.7 days with ranging from 3 to 10 days.Conclusion: Region based bacteroiological diagnosis of Cap is important for selecting the best and sensitive drugs for complete cure.J Bangladesh Coll Phys Surg 2016; 34(3): 128-134

scholarly journals Mutations in domain V of Mycoplasma pneumoniae 23S rRNA are not associated with clinical characteristics of M. pneumoniae pneumonia in children: a case control study

2020 ◽  
Author(s):  
Huan Deng ◽  
Yifan Zhu ◽  
Jiamin Zhang ◽  
Qiangquan Rong ◽  
Yao Quan ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Lymphocyte Count ◽  
Clinical Characteristics ◽  
Clinical Symptoms ◽  
Laboratory Data ◽  
Point Mutations ◽  
Community Acquired Pneumonia ◽  
Pulmonary Complications ◽  
23S Rrna ◽  
Domain V

Abstract Background Mycoplasma pneumoniae (MP) is a common agent of community-acquired pneumonia in children and young adults that can lead to refractory or persistent Mycoplasma pneumoniae pneumonia (MPP). Macrolide-resistant MP harbors point mutations in domain V of 23S ribosomal Ribonucleic Acid (rRNA) with substitutions detected at positions 2063, 2064, 2067 and 2617. This study’s purpose is to investigate the prevalence and clinical characteristics of mutations in domain V of MP 23S rRNA. Methods We sequenced the 23S rRNA domain V of MP strains collected from children with MPP. Clinical and laboratory data were also obtained, including gender, age, duration of fever, duration of fever after the start of macrolide therapy, MP-Deoxyribonucleic Acid (DNA) load at enrollment, leukocyte count, neutrophil count, and lymphocyte count, immunomodulators treatment and pulmonary complications.Results Of 276 strains, 255 (92.39 %) harbored A to G transition at the position 2063 (A2063G), and 21 (7.61 %) were not mutated. There were no significant differences in gender, age, duration of fever, duration of fever after the start of macrolide therapy, MP-DNA load at enrollment, hospitalization days, lymphocyte count and pulmonary complications when patients were stratified based on the presence or absence of domain V mutations. We also found that children with refractory MPP experienced higher MP-DNA load than the non-refractory MPP, but the prevalence of domain V mutations was comparable.Conclusions We found that clinical MP strains harbored very high mutation rate in 23S rRNA domain V, especially A2063G mutation. However, these mutations were not associated with clinical symptoms, laboratory results, pulmonary complications and development of refractory pneumonia. Instead, MP-DNA load was significantly different between refractory and non-refractory MPP.

scholarly journals Effect of 23S rRNA gene mutations in Mycoplasma pneumoniae on severity of community-­acquired pneumonia in young adult patients treated at the Smolensk military hospital

2020 ◽  
Vol 22 (4) ◽  
pp. 306-312
Author(s):  
O.V. Ivanova ◽  
Inna A. Edelstein ◽  
O.I. Romashov ◽  
Roman S. Kozlov
Keyword(s):  
Young Adult ◽  
Mycoplasma Pneumoniae ◽  
Gene Mutations ◽  
Community Acquired Pneumonia ◽  
Adult Patients ◽  
23S Rrna ◽  
Military Hospital ◽  
Rrna Gene ◽  
Resistant Genotype ◽  
23S Rrna Gene

Objective. To evaluate effect of 23S rRNA gene mutations in Mycoplasma pneumoniae on severity of community-acquired pneumonia (CAP) in young adult patients. Materials and Methods. A total of 42 case histories of young adult patients with CAP treated at the Smolensk military hospital over the period of 25 October 2017 to 25 December 2019 were reviewed. «AmpliSens® Mycoplasma pneumoniae/Chlamydophila pneumoniae-FL» real-time PCR kit was used to detect M. pneumoniae from nasopharyngeal swabs collected prior to antimicrobial therapy. Testing for 23S rRNA gene mutations conferring macrolide resistance was performed by real-time PCR melt curve analysis (patent no. 2646123) and confirmed by DNA sequencing. Results. All patients had a clinical picture of non-severe CAP on hospital admission. All patients were treated with standard doses of azithromycin or clarithromycin. No respiratory failure or any other complications were observed. Macrolide-resistant genotype of M. pneumoniae was detected in 4 (9.5%) patients. Clinical, laboratory and radiological resolution of pneumonia in all cases occurred on day 10– 16, regardless of the presence of macrolide-resistant genotype. Conclusions. There were no differences in clinical course of severity between CAP caused by M. pneumoniae with 23S rRNA gene mutation and CAP caused by wild-type M. pneumoniae The presence of mutations in the 23S rRNA gene of M. pneumoniae did not worsen the clinical course of CAP.

Sign in / Sign up

Export Citation Format

Share Document